---
document_datetime: 2026-01-06 10:44:31
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vaxneuvance-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vaxneuvance-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.9633803
conversion_datetime: 2026-01-10 11:33:38.378539
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vaxneuvance

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 10/12/2025                          | N/A                                         | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000308795                     | PRODUCTS - C.I.z Other variation - Accepted To provide a clarification of the instructions for use in sections 6.6 of the Summary of Product Characteristics and in section 'The following information is intended for healthcare professionals only' of the Package Leaflet. In addition the annexes have been updated to the current excipient guidance for polysorbate 20. The MAH as also taken this opportunity to make amendments to the contact details for the local representatives in BG, CS, EL, ES, HR, CY, HU, IS, MT, AU, PL, PT, RO, SL, SK and have removed the representative for UK(NI).   |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000291037 | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted                                                                                                                                                                                                                                                                  | 23/10/2025 | N/A |
| Variation type IB / EMA/VR/0000286313 | B.I.e.5 Implementation of changes foreseen in an approved change management protocol - B.I.e.5.c Implementation of a change for a biological/immunological medicinal product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                      | 28/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000285849   | B.I.c.2 Change in the specification parameters and/or limits of the immediate packaging of the active substance - B.I.c.2.c Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) - Accepted   | 28/07/2025   | N/A   |             |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|
| Variation type IB / EMA/VR/0000249311   | B.I.e.5 Implementation of changes foreseen in an approved change management protocol - B.I.e.5.c Implementation of a change for a biological/immunological medicinal product - Accepted                                                 | 11/03/2025   | N/A   |             |
| PSUR / EMA/PSUR/0000268990              | - -                                                                                                                                                                                                                                     |              |       | Maintenance |